Business Case | Global Regulatory Support for a Multiregional Medicinal Product Program
Development & Scientific Writing Week
Asphalion’s Medical and Scientific Writing team provides you with support to build the foundations of strong non-clinical and clinical developments.
Our team has has academic research experience and a broad scientific background in non-clinical, clinical and CMC writing for different types of products, including innovative, biological, biotechnological and advanced therapies medicinal products. Asphalion’s expertise allows us to offer the best regulatory strategy for each project.
We can support you with all sort of regulatory related documentation required during the clinical development and registration. In addition to this, strategic inputs can be provided from the very beginning for segmentation/niche indication, conditional approval/fast track, orphan drug designations, preclinical and clinical development plans with minimal time-to-market, among others.
Medical and Scientific Writing Solutions
We provide specialized expertise in key areas, ensuring a smooth and efficient path to product approval and commercial success:
Schedule a free meeting!
Discuss your case with our experts and receive a valuable feedback
Share
Why Asphalion?
Related Resources
Development & Scientific Writing Week
Development and Scientific Writing Week
Development and Scientific Writing Week
Development & Scientific Writing Week
Transition to Clinical Trials Regulation EU 536/2014 and CTIS
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
Webinar recording
Asphalion End to End support during product lifecycle
Elevating Safety Standards Across Medicinal Products and Medical Devices
Asphalion experts Jon Giblin and Christopher Mann, together with experts from the ARDAT Consortium, have just published an article on Molecular Therapy. “Currently, most clinical trials for adeno-associated virus (AAV)-based
After four years of research into Polyendocrine Metabolic Ovarian Syndrome (PMOS) (previously known as polycystic ovary syndrome (PCOS)), the SPIOMET4HEALTH Final Policy Event will bring together researchers, patients, patient organisations
Biosimilars are biological medicines that are highly similar in structure, biological activity, safety, and effectiveness to an already approved originator biological medicine (“reference medicine”). Globally, they play an important role
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
